Board summary
Key figures
33,248
Registered population
61.4% aged 18–64
16.0%
Aged 65+
ICB 19.9% · England 17.9%
28.4%
Ethnic minority (non-White)
11.0% Asian · England 9.6%
12.3%
In IMD quintile 1
ICB 17.1% · England 21.0%
~3,553
Core20 residents (est.)
Resident basis; registered basis ~4,109 · see page 3
5,711
Hypertension register
-1.70% in 3 yrs · England +5.60%
299
SMI register
27% of Dartford's
652
COPD register
Reviews -9.15% in 3 yrs
Forecast to 2030
5,906
Hypertension patients, 2030
+195 on today
68.6%
QRISK ≥20% on statins, 2030
-0.57pp over 3 yrs
3.6%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Age-5 MMR2 coverage trails first dose.
In Q1 2025/26, age-5 MMR2 coverage is 72.3% (England 82.8%), 16.9 pp below MMR1 (89.2%), which may reflect recall gaps to verify locally.
Heart failure annual reviews fell sharply.
Annual heart failure reviews reach 61.6% (Dartford 69.6%, ICB 75.0%, England 78.5%) and fell 20.7% over 2023 to 2025 against England (+8.7%).
Diabetes statin prescribing exceeds national benchmarks.
Statin therapy in diabetes reaches 80.9% without CVD (Dartford 73.8%, ICB 72.0%, England 73.2%) and 87.5% with CVD (England 84.4%).
Population, age and ethnicity
A younger, diverse population coincides with expanding learning disability registers and care beds
Across 33,248 registered patients in three practices, 22.6% are aged 0-17 (Dartford 23.3%, ICB 20.7%, England 19.6%) and 16.0% are aged 65+ (Dartford 15.1%, ICB 19.9%, England 17.9%). Practice scale spans 7,456 to 15,087 patients. Area Census estimates for usual residents in associated areas indicate a 28.4% ethnic minority share, including 11.8% Black (Dartford 10.5%, ICB 3.1%, England 4.2%) and 11.0% Asian residents (Dartford 9.9%, ICB 4.7%, England 9.6%).
Age profile
65+: ICB 19.9%, England 17.9%
Ethnicity
Older people · falls rows are Dartford local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Dartford LA) | 2,006 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 79.1% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 56.7% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Dartford LA) | 1,000 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Dartford LA) | 14.2 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
PCN Core20 share is 12.3%, but practice shares span 18.6 percentage points
The PCN Core20 share of registered patients is 12.3%, below England (21.0%) and NHS Kent and Medway ICB (17.1%), but above Dartford (9.8%). However, practice shares span 18.6 percentage points: Lowfield Medical Centre has the highest concentration at 24.86% (1,854 estimated Core20 patients), while Dr Cj Shimmins & Partners has 10.53% (1,589 estimated patients) and The Wellcome Practice has 6.22% (666 estimated patients). Resident estimates (3,553) and registered sums (4,109) differ by population base. Prioritising support solely by concentration risks overlooking large patient volumes.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
299
SMI register
0.87% recorded prevalence
191
Learning disability register
0.56% recorded prevalence
13
Care homes, 625 beds
In the PCN catchment
8.6%
Provide unpaid care
Dartford, Census 2021
Recorded severe mental illness covers 299 patients (0.9%; Dartford 0.8%, ICB 0.9%, England 1.0%). The learning disability register has 191 patients (0.6%), rising +15.3% over 2023 to 2025 (Dartford -1.6%, ICB +4.5%, England +5.4%). The catchment includes 13 care homes with 625 beds (occupancy and resident registrations unrecorded). Faster learning disability register growth than England prioritises structured annual health check capacity.
Severe mental illness: physical health checks
Recorded SMI prevalence is 0.9%. Annual blood pressure checks reached 75.9%, below England (83.4%) and Dartford (78.5%), and 65.6% at Dr Cj Shimmins & Partners, while BMI checks reached 80.6%. Focused recall could help close recorded blood pressure check disparities.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
5,711
Hypertension register
−1.70%
Register growth, 3 yrs
Dartford +7.12% · England +5.60%
−3.99pp
BP control, under 80
≤140/90 · +2.14pp aged 80+
+195
More patients by 2030
Forecast 5,906 (16.07%)
Hypertension case-finding and control
Hypertension QOF prevalence is 16.6% (5,711 patients), exceeding England (15.2%), Dartford (15.9%) and NHS Kent and Medway ICB (16.2%), though prevalence fell 1.7% over 2023 to 2025 (England +5.6%). Under-80 blood pressure control is 65.6%, trailing England (67.8%) after falling 5.7% (England +3.2%), spanning from 62.1% at Dr Cj Shimmins & Partners to 70.5% at Lowfield Medical Centre, whereas over-80 control reached 84.5% (England 81.2%). Heart failure annual reviews fell 20.7% to 61.6% (England 78.5%, +8.7%). Denominators include personalised care adjustments. Trailing under-80 blood pressure control and falling heart failure reviews indicate room to review proactive recall and monitoring across practices.
Lipids and statins
Lipid-lowering therapy reaches 69.7% for patients with QRISK ≥ 20% (England 63.6%), with diabetes statin coverage at 80.9% without CVD (England 73.2%) and 87.5% with CVD (England 84.4%). QRISK therapy fell 0.8% over 2023 to 2025 (England +6.2%). Stronger statin uptake than England provides an opportunity to maintain primary prevention while addressing slower three-year growth.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 48,752 | £2.00 | £1.90 | £1.86 | £97,504 |
| Cardiovascular (all), 2025 | 60,133 | £3.99 | £3.57 | £3.33 | £239,931 |
For lipid-regulating drugs in 2026, the PCN prescribed 48,752 items at £2.00 per item, compared to £1.86 in England, £1.79 in Dartford, and £1.90 in NHS Kent and Medway ICB, spending £6,825 more than at England's unit cost. This unit-cost indicator reflects formulary mix rather than realized inefficiency, as unit cost does not evaluate case-mix.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−0.47%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−2.18%
Asthma prevalence, PCN 3-yr % change
Asthma prevalence is 5.5% (register 1,788), but 12-month reviews reached 58.0%, below England (65.7%) and Dartford (60.8%), leaving about 750 patients unreviewed; practice rates range from 50.1% at Dr Cj Shimmins & Partners to 74.6% at Lowfield Medical Centre. For ages 5 to 19, asthma prescribing is 838 items per 1,000 (England 1,488). COPD reviews fell 9.2% over 2023 to 2025 (England +2.8%) to 66.4% (England 76.4%). Proactive respiratory review recall is needed across all practices to reverse declining review coverage.
Cancer register and children's immunisation
Cancer prevalence is 3.2% (1,105 patients; England 3.8%). In Q1 2025/26, complete 6-in-1 immunisation at 24 months reached 97.5%, exceeding the 95.0% target by 2.5 pp. Conversely, at age 5, MMR dose 2 and 4-in-1 booster coverage were both 72.3%, trailing the target by 22.7 pp with an MMR dose drop of 16.9 pp across the PCN. Prioritising pre-school booster call and recall is required to restore secondary coverage before school entry.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Kent and Medway ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~1,630
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Kent and Medway ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Breast | 82.1% | 85.4% | 23% | 1,509 |
| Prostate | 54.4% | 53.2% | 37% | 1,435 |
| Lung | 29.4% | 33.8% | 21% | 1,109 |
| Bowel | 48.2% | 47.0% | 29% | 1,013 |
| Skin cancer | 87.5% | 87.8% | 23% | 562 |
Across NHS Kent and Medway ICB in 2022, 55.6% of cancers with a known stage were diagnosed at stage 1 or 2 (4,661 of 8,384 cases), compared with England (55.3%) and 19.4 pp below the 75.0% national ambition. Reaching 75.0% would require about 1,630 additional early-stage diagnoses annually across the ICB. Known-stage share was 63.6% (England 67.0%). Within Dartford Model PCN, cervical screening coverage aged 25-49 is 67.4% (ICB 69.9%, England 66.8%), falling to 64.6% at Dr Cj Shimmins & Partners. Lower screening uptake could contribute to delayed detection across wider system pathways.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In provisional data for Jul 2026, Dartford and Gravesham NHS Trust achieved 63.6% on the 62-day cancer referral to treatment standard, trailing King's College Hospital NHS Foundation Trust (70.1%), England (71.2%), and NHS Kent and Medway Integrated Care Board (75.9%), sitting 21.4 pp below the 85.0% standard. The trust met the 28-day faster diagnosis standard at 78.1% (standard 75.0%) and the 31-day combined treatment standard at 97.5% (standard 96.0%). For diagnostic tests in Jul 2026, 8.4% of patients waited 6+ weeks at the trust (England 23.1%). These hospital figures reflect provider activity, not PCN-specific performance.
| Pathways within standard (%) | Dartford and Gravesham | King's College | Kent and Medway ICB | England |
|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 78.14 | 80.68 | 76.78 | 79.32 |
| 31-day treatment (96%) | 97.48 | 96.68 | 95.84 | 92.50 |
| 62-day referral to treatment (85%) | 63.59 | 70.15 | 75.93 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Dartford and Gravesham | Kent Health | King's College | England |
|---|---|---|---|---|
| MRI | 0.36 | — | 21.22 | 21.40 |
| CT | 2.08 | — | 22.60 | 9.92 |
| Echocardiography | 3.90 | — | 14.39 | 28.48 |
| Colonoscopy | 0.40 | — | 41.81 | 30.83 |
| Gastroscopy | 0.00 | — | 35.98 | 29.02 |
| All 15 DM01 tests | 8.37 | 27.49 | 19.15 | 23.14 |
| Community services activity | Kent residents | Kent and Medway ICB |
|---|---|---|
| Care contacts | 210,170 | 254,055 |
| Referrals | 59,360 | 68,085 |
| Patients with a contact | 60,605 | 72,060 |
Community services (residents of Kent), Jun 2026 (provisional). Provisional experimental CSDS data for Jun 2026 record 210,170 community care contacts across Kent covering 60,605 patients, with 265,905 care activities. NHS Kent and Medway Integrated Care Board recorded 254,055 contacts and 297,595 activities. Older adults aged 65+ accounted for 65.8% of borough residents' contacts (138,250 of 210,170). These figures reflect regional provider activity, not unique PCN patient activity.
Practice variation and patient experience
Patient experience varies by 24.3 pp across practices alongside marked differences in access
In 2025/26, clinical QOF achievement was 99.7% at Lowfield Medical Centre and 100.0% at Dr Cj Shimmins & Partners and The Wellcome Practice (England 97.1%). Vaccination and immunisation achievement ranged from 15.6% at Dr Cj Shimmins & Partners and The Wellcome Practice to 20.8% at Lowfield Medical Centre (England 55.2%).
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Dr Cj Shimmins & | 88 | 10.5 | 56.8% | 59.9% | 79.5% |
| Wellcome | 106 | 6.2 | 33.9% | 76.0% | 76.6% |
| Lowfield | 114 | 24.9 | 38.4% | 86.6% | 55.1% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Thirteen of 25 tracked measures trail England three-year progress despite screening gains
Across 25 tracked measures, 13 trail England's three-year change. The sharpest lags appear in chronic condition management: heart failure reviews fell 20.7% over 2023 to 2025 (England +8.7%), COPD reviews fell 9.2% (England +2.8%), and hypertension treated to target fell 5.8% (England +3.6%). Conversely, breast screening rose +25.6% over 2023 to 2024 (England +8.4%), while diabetes statin therapy without CVD rose +7.0% (England +2.1%) and psychosis alcohol recording rose +13.6 pp (England +5.4 pp). Trailing three-year review rates may indicate recall gaps; auditing practice recall systems would test whether scheduling barriers explain falling coverage.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Heart failure reviews
COPD reviews
Hypertension treated to target
BP control, under 80
Hypertension register
Breast screening (53-70)
Alcohol record (psychosis)
Diabetes statin (no CVD)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Dartford | Asset | PCN | Dartford |
|---|---|---|---|---|---|
| Care homes (catchment) | 13 (625 beds) | n/a | Schools (catchment) | 70 | n/a |
| Children's centres | 5 | 7 | Places of worship | 31 | 41 |
| Libraries | 3 | 7 | Homelessness support (VCS) | n/a | 1 |
| Day centres (VCS) | 5 | 5 | Children and young people (VCS) | 1 | 1 |
| Carers support groups (VCS) | n/a | 3 | Primary schools (LA maintained) | 3 | 6 |
| Primary academies | 14 | 22 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Proactive asthma annual review recall
Asthma 12-month reviews (register 1,788) reached 58.0% (denominator incl. PCAs), below England (65.7%) by 7.6 pp and Dartford (60.8%) by 2.8 pp, leaving about 750 patients unreviewed. Low cost, quick to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Pre-school MMR2 and booster recall
At age 5 in Q1 2025/26 (cohort 83), MMR2 and 4-in-1 coverage are both 72.3%, 22.7 pp below the 95.0% target and 16.9 pp below MMR1 (89.2%), with a 21.6 pp drop at Dr Cj Shimmins & Partners. Low cost, quick to run.
Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.
Policy anchor: 10 Year Health Plan, shift from sickness to prevention.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Diverse community health outreach (p2) | Black / African / Caribbean / Black British | Neighbourhood health framework · Core20PLUS5 approach | PCN |
| Targeted Core20 resource allocation (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| Physical health checks for SMI (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Under-eighty blood pressure recall (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school booster recall (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall audit (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Telephony and access review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Proactive asthma annual review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN & Practice |
| Option 2 · Pre-school MMR2 and booster recall (p12) | MMR dose 1 coverage at age 5 · MMR dose 2 coverage at age 5 · 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
